Phase 3 Readout

GSK: Phase 3 Topline: A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety S

Name: Phase 3 Topline: A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety S
Start: 2027-03-17
End: 2027-03-17

March 17, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: March 17, 2027
Company: GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety S

March 17, 2027

GSK overview →

Company: GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
Indication: Cough; Refractory Chronic Cough